These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18279115)

  • 1. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.
    Moyneur E; Bookhart BK; Mody SH; Fournier AA; Mallett D; Duh MS
    Dis Manag; 2008 Feb; 11(1):49-58. PubMed ID: 18279115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
    Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
    J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
    Padullés-Zamora N; Comas-Sugrañes D; Pineda-Yuste Mdel M; Jódar-Masanés R; Martínez-Castelao A
    Nefrologia; 2012; 32(2):221-7. PubMed ID: 22421952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
    Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
    Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.